Atlas Trials

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Clinical trial NCT01567709 · COMPLETED

Trial details

NCT number
NCT01567709
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Adult B Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaChronic Lymphocytic LeukemiaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHepatosplenic T-Cell LymphomaIntraocular LymphomaLymphomatous Involvement of Non-Cutaneous Extranodal SiteMature T-Cell and NK-Cell Non-Hodgkin LymphomaNodal Marginal Zone LymphomaPrimary Cutaneous B-Cell Non-Hodgkin Lymphoma
Start date
2012-04-16
Primary completion
2018-03-29
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.